Royal Bank Of Canada Nymox Pharmaceutical Corp Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.19 - $0.49 $271 - $700	1,430 New	1,430 $0
Q3 2022 Nov 14, 2022	BUY	$0.22 - $0.61 $143 - $398	653 Added 391.02%	820 $0
Q3 2021 Nov 15, 2021	SELL	$1.3 - $2.23 $11,260 - $19,316	-8,662 Reduced 98.11%	167 $0
Q2 2021 Aug 16, 2021	BUY	$1.46 - $2.48 $12,890 - $21,895	8,829 New	8,829 $14,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.